Core Insights - iBio, Inc. will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Miami, highlighting its focus on advancing its next-generation obesity pipeline [1][2]. Company Overview - iBio is an AI-driven biotech company specializing in precision antibody therapies for cardiometabolic diseases, obesity, cancer, and other challenging conditions [4]. - The company utilizes proprietary 3D modeling and innovative drug discovery platforms to develop breakthrough antibody treatments aimed at significant unmet medical needs [4]. Key Events - Martin Brenner, CEO and Chief Scientific Officer of iBio, will engage in a fireside chat on December 4, 2025, discussing the promising non-human primate data for IBIO-610, a potential first-in-class Activin E antibody [2]. - Felipe Duran, CFO of iBio, will be available for one-on-one meetings during the conference, providing opportunities for direct engagement with investors [3]. Additional Information - A livestream of the conference will be available, and a replay will be posted on the Investor section of the iBio website [3].

Core Viewpoint - iBio, Inc. has announced a public offering of pre-funded warrants and accompanying Series G and Series H warrants, aiming to raise approximately $50 million to advance its preclinical programs and support working capital needs [1][3][4]. Offering Details - The offering includes pre-funded warrants for 71,540,000 shares and Series G warrants for 35,770,000 shares, with a combined public offering price of $0.699 per unit [1][3]. - The estimated gross proceeds from the offering are expected to be around $50 million before deducting underwriting discounts and commissions [3]. - The offering is expected to close on or about August 22, 2025, subject to customary closing conditions [1]. Warrant Specifications - Pre-funded warrants are immediately exercisable until fully exercised, while Series G and Series H warrants will have an exercise price of $0.70 per share [2]. - Series G warrants will expire either 30 trading days after a significant trial initiation announcement or five years from issuance [2]. Use of Proceeds - iBio plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and to fund working capital and other corporate purposes [4]. Underwriters - Leerink Partners is the lead bookrunner for the offering, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers [5].